<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797090</url>
  </required_header>
  <id_info>
    <org_study_id>Moustafa Omara</org_study_id>
    <nct_id>NCT05797090</nct_id>
  </id_info>
  <brief_title>Comparative Study Between Conventional Crystalloid Cardioplegic Solution With Modified Del Nido Cardioplegia</brief_title>
  <official_title>Comparative Study Between Conventional Crystalloid Cardioplegic Solution With Modified Del Nido Cardioplegia in Mitral Valve Regurgitation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mohamed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azhar University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azhar University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitral valvuloplasty for correction of chronic mitral regurgitation carries a lower operative&#xD;
      mortality and morbidity and improved long-term survival than does mitral valve replacement.&#xD;
      Unfortunately, mitral valvuloplasty is not possible in all patients with chronic mitral&#xD;
      regurgitation because of unfavorable pathology or lack of experience with this technique&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardioplegia is a fundamental component in providing heart protection, limiting metabolic&#xD;
      activity and increasing the myocardium's capacity to resist ischemia for prolonged periods,&#xD;
      thus being essential for good surgical outcomes.&#xD;
&#xD;
      Numerous cardioplegia solutions exist with different compositions to provide sufficient&#xD;
      myocardial protection. However, there is no standard for the optimal or ideal composition and&#xD;
      delivery technique. Cardioplegia solutions are crystalloid or blood-based solutions with&#xD;
      various chemical compounds.&#xD;
&#xD;
      Despite improvements in myocardial protection, prosthetic valves, surgical techniques, and&#xD;
      postoperative care, the operative mortality and morbidity of mitral valve replacement for&#xD;
      chronic mitral regurgitation remains high in comparison with other commonly performed heart&#xD;
      operations.&#xD;
&#xD;
      The timing of the administration of cardioplegia is extremely important in terms of&#xD;
      preventing myocardial dysfunction. Conventional multidose cardioplegias should be repeatedly&#xD;
      administered in every 15 to 20 min. Frequent interruption of the surgical process, even for a&#xD;
      short time, before each cardioplegia delivery leads to a loss of time during open heart&#xD;
      surgery, where time is extremely important, and disrupts the coherence of the operation and&#xD;
      the surgical concentration.&#xD;
&#xD;
      Crystalloid cardioplegic solutions achieve cardioplegic arrest through inhibition of either&#xD;
      fast-acting sodium channels or calcium-activated mechanisms. Hyperkalemia can be used to&#xD;
      inhibit the fast-acting sodium channels as it is in the St.Thomas Hospital solution and its&#xD;
      modifications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Actual">March 15, 2023</completion_date>
  <primary_completion_date type="Actual">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myocardial protection</measure>
    <time_frame>from baseline to 24 hours after the operation</time_frame>
    <description>Number of Participants With myocardial protection through measurements of the serum levels of the cardiac enzymes just after operation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Mitral Valve Surgery</condition>
  <arm_group>
    <arm_group_label>crystalloid cardioplegia with modified del Nido cardioplegia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crystalloid Cardioplegic solution</intervention_name>
    <description>To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.</description>
    <arm_group_label>crystalloid cardioplegia with modified del Nido cardioplegia</arm_group_label>
    <other_name>Modified Del Nido Cardioplegia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients scheduled for elective Mitral regurge replacement Surgery with normal Coronaries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with chronic renal disease (previous medical diagnosis or serum creatinine&#xD;
             greater than 1.5mg/dL)&#xD;
&#xD;
          2. Left ventricular ejection fraction less than 50%.&#xD;
&#xD;
          3. Previous cardiac surgery&#xD;
&#xD;
          4. Patient with BMI &gt; 30&#xD;
&#xD;
          5. Severe psychiatric illness&#xD;
&#xD;
          6. Inability or unwillingness to give informed consent for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Abdel-Gawad, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine - Al-Azhar University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azhar University</name>
      <address>
        <city>Cairo</city>
        <zip>11765</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>February 25, 2023</study_first_submitted>
  <study_first_submitted_qc>April 1, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>May 3, 2023</last_update_submitted>
  <last_update_submitted_qc>May 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azhar University</investigator_affiliation>
    <investigator_full_name>mohamed</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, intensive care and pain management Faculty of Medicine - Al-Azhar University</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardioplegic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

